Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer

被引：0

作者：

Cucevic, B

Samarzija, M

Baricevic, D

Jakopovic, M

Redzepi, G

Samija, M

机构：

[1] Univ Zagreb, Univ Hosp Lung Dis Jordanovac, HR-10002 Zagreb, Croatia

[2] Univ Zagreb, Univ Hosp Tumors, HR-10002 Zagreb, Croatia

来源：

COLLEGIUM ANTROPOLOGICUM | 2005年 / 29卷 / 02期

关键词：

gemcitabine; lung cancer; NSCLC; chemotherapy;

D O I：

暂无

中图分类号：

Q98 [人类学];

学科分类号：

030303 ;

摘要：

Aim of this study was to estimate efficacy of gemcitabine in first and the second-line chemotherapy for patients with advanced non-small cell lung cancer (stage III and TV). In first-line chemotherapy, 120 patients were treated with different chemotherapy regimens. Fifty-nine patients were treated with gemcitabine / cisplatin (PG), 41 with cisplatin I etoposide (PE) and 20 with mitomycin / ifosamide / cisplatin (MIC). Forty patients, unsuccessfully treated with PE and MIC in first-line therapy were treated with PG (24 pts) and with best supportive care (BSC) (16 pts). In first-line therapy PG was superior to PE and MIC protocol (mean survival (MS) 10 vs. 7 vs. 8.5 months). Response rate (RR) for PG in first-line therapy was 46% and 21% in second-line. We showed also significantly better survival in patients treated with PG in second-line chemotherapy comparing to best supportive care (MS 9 us. 5.5 months). Toxic side effects for combination PG was acceptable. This study confirmed that PG combination is safe and effective as first and seeond-line chemotherapy for patients with advanced non-small cell lung cancer.

引用

页码：583 / 588

页数：6

共 50 条

[31] Advanced non-small cell lung cancer. Maintenance and second-line treatment
Schuette, W.
Nagel, S.
Haak, G.
Steinert, M.
PNEUMOLOGE, 2012, 9 (01): : 43 - 48
[32] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
J. Feliu
G. Martín
J. Castro
A. Sundlov
A. Rodriguez-Jaráiz
E. Casado
M. Lomas
C. Madroñal
A. Galán
C. Belda
M. Gonzalez-Barón
Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
[33] Second-line treatment for advanced non-small cell lung cancer:: A systematic review
Barlési, F
Jacot, W
Astoul, P
Pujol, JL
LUNG CANCER, 2006, 51 (02) : 159 - 172
[34] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
Feliu, J.
Martin, G.
Castro, J.
Sundlov, A.
Rodriguez-Jaraiz, A.
Casado, E.
Lomas, M.
Madronal, C.
Galan, A.
Belda, C.
Gonzalez-Baron, M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
[35] Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
Reckamp, Karen L.
CANCER LETTERS, 2012, 321 (02) : 101 - 109
[36] A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
Kotsakis, Athanasios
Hatzidaki, Dora
Vamvakas, Lambros
Vardakis, Nikolaos
Kalykaki, Antonia
Bozionelou, Vasiliki
Androulakis, Nikolaos
Kalbakis, Kostas
Saridaki, Zacharenia
Georgoulias, Vassilis
Agelaki, Sophia
ANTICANCER RESEARCH, 2010, 30 (10) : 4335 - 4342
[37] A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
Sculier, JP
Lafitte, JJ
Berghmans, T
Thiriaux, J
Lecomte, J
Efremidis, A
Ninane, V
Paesmans, M
Mommen, P
Klastersky, J
LUNG CANCER, 2000, 29 (01) : 67 - 73
[38] First- and second-line biomarker utilization in non-small cell lung cancer
Leong, Matthew
Azimpouran, Mahzad
McCloskey, Audrey
Sankar, Kamya
Vail, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Oral second-line chemotherapy for advanced non-small-cell lung cancer: The bottom line
Gandara, David R.
Davies, Angela M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2700 - 2701
[40] Second-line chemotherapy with gemcitabine and uracil/tegafur for relapsed or refractory non-small cell lung cancer: a phase II study
Tanaka, H.
Tanaka, J.
Itoh, R.
Kuriyama, H.
Kagamu, H.
Itoh, K.
Sato, K.
Nakata, K.
Gejyo, F.
Yoshizawa, H.
EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375

← 1 2 3 4 5 →